US2023203199A1PendingUtilityA1

Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof

Assignee: MODEX THERAPEUTICSPriority: Sep 29, 2021Filed: Sep 28, 2022Published: Jun 29, 2023

Est. expirySep 29, 2041(~15.2 yrs left)· nominal 20-yr term from priority

Inventors:Ronnie Wei Ling Xu Zhi-Yong Yang Edward Seung Gary J. Nabel Lan Wu Mark Greci Hao Chen

C07K 16/1145C07K 16/116C07K 16/108C07K 16/106C07K 16/11C07K 2319/50C07K 2317/71C07K 2317/64C07K 2317/626C07K 2317/56C07K 2317/31A61P 31/18C07K 16/2896C07K 16/2887C07K 16/2818C07K 16/2809C07K 16/2803C07K 2317/73C07K 2317/622C12N 5/0636A61P 35/00C07K 16/468C07K 2317/92C07K 16/00C07K 16/46C07K 2317/62A61P 31/12C07K 16/2866C07K 16/2878C07K 16/3076C07K 16/082C07K 16/087C07K 16/125C07K 16/1253C07K 16/1275C07K 16/1285C07K 19/00C07K 2317/21C07K 2317/24C07K 2319/41C07K 2319/42C07K 2319/43C12N 2502/30

PatentIndex Score

Cited by

References

Claims

Abstract

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, chimeric antigen receptors (CARs), immune cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

Claims

exact text as granted — not AI-modified

1 - 127 . (canceled) 
     
     
         128 . An antigen binding polypeptide complex comprising a first polypeptide and a second polypeptide;
 wherein the first polypeptide has a structure represented by:   VL1-VL2-VH2-VH1-Fc;   VH1-VH2-VL2-VL1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-Fc; or   VH1-L1-VH2-L2-VL2-L3-VL1-L4-Fc;   wherein the second polypeptide has a structure represented by:   VL3-VL4-VH4-VH3-Fc;   VH3-VH4-VL4-VL3-Fc;   VL3-L5-VL4-L6-VH4-L7-VH3-Fc;   VH3-L5-VH4-L6-VL4-L7-VL3-Fc;   VL3-L5-VL4-L6-VH4-L7-VH3-L8-Fc; or   VH3-L5-VH4-L6-VL4-L7-VL3-L8-Fc; and   wherein:   VL1 is a first immunoglobulin light chain variable region;   VL2 is a second immunoglobulin light chain variable region;   VL3 is a third immunoglobulin light chain variable region;   VL4 is a fourth immunoglobulin light chain variable region;   VH1 is a first immunoglobulin heavy chain variable region;   VH2 is a second immunoglobulin heavy chain variable region;   VH3 is a third immunoglobulin heavy chain variable region;   VH4 is a fourth immunoglobulin heavy chain variable region;   Fc is a region comprising an immunoglobulin heavy chain constant region 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), and optionally, an immunoglobulin hinge; and   L1, L2, L3, L4, L5, L6, L7 and L8 are amino acid linkers.   
     
     
         129 . The antigen binding polypeptide complex of  claim 128 ,
 wherein the first polypeptide has a structure represented by:   VL1-VL2-VH2-VH1-CH1-Fc;   VH1-VH2-VL2-VL1-CH1-Fc;   VL1-VL2-VH2-VH1-CL-Fc;   VH1-VH2-VL2-VL1-CL-Fc;   VL1-VL2-VH2-VH1-CH1-CL-Fc;   VH1-VH2-VL2-VL1-CH1-CL-Fc;   VL1-VL2-VH2-VH1-CL-CH1-Fc;   VH1-VH2-VL2-VL1-CL-CH1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc;   wherein the second polypeptide has a structure represented by:   VL3-VL4-VH4-VH3-CH1-Fc;   VH3-VH4-VL4-VL3-CH1-F c;   VL3-VL4-VH4-VH3-CL-Fc;   VH3-VH4-VL4-VL3-CL-F c;   VL3-VL4-VH4-VH3-CH1-CL-Fc;   VH3-VH4-VL4-VL3-CH1-CL-F c;   VL3-VL4-VH4-VH3-CL-CH1-Fc;   VH3-VH4-VL4-VL3-CL-CH1-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-Fc;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-L12-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-L12-Fc;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-L12-Fc; or   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-L12-F c; and   wherein:   CH1 is an immunoglobulin heavy chain constant region 1;   CL is an immunoglobulin light chain constant region; and   L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 and L12 are amino acid linkers.   
     
     
         130 . An antigen binding polypeptide complex comprising a first polypeptide and a second polypeptide;
 wherein the first polypeptide has a structure represented by:   VL1-VL2-VH2-VH1-Fc;   VH1-VH2-VL2-VL1-Fc;   VL1-VL2-VH2-VH1-CH1-Fc;   VH1-VH2-VL2-VL1-CH1-Fc;   VL1-VL2-VH2-VH1-CL-Fc;   VH1-VH2-VL2-VL1-CL-Fc;   VL1-VL2-VH2-VH1-CH1-CL-Fc;   VH1-VH2-VL2-VL1-CH1-CL-Fc;   VL1-VL2-VH2-VH1-CL-CH1-Fc;   VH1-VH2-VL2-VL1-CL-CH1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CH1-L5-CL-L6-Fc;   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CH1-L5-CL-L6-Fc;   VL1-L1-VL2-L2-VH2-L3-VH1-L4-CL-L5-CH1-L6-Fc; or   VH1-L1-VH2-L2-VL2-L3-VL1-L4-CL-L5-CH1-L6-Fc;   wherein the second polypeptide has a structure represented by:   VL3-VL4-VH4-VH3-Fc;   VH3-VH4-VL4-VL3-F c;   VL3-VL4-VH4-VH3-CH1-Fc;   VH3-VH4-VL4-VL3-CH1-F c;   VL3-VL4-VH4-VH3-CL-Fc;   VH3-VH4-VL4-VL3-CL-F c;   VL3-VL4-VH4-VH3-CH1-CL-Fc;   VH3-VH4-VL4-VL3-CH1-CL-F c;   VL3-VL4-VH4-VH3-CL-CH1-Fc;   VH3-VH4-VL4-VL3-CL-CH1-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-Fc;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-Fc;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-F c;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CH1-L11-CL-L12-Fc;   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CH1-L11-CL-L12-Fc;   VL3-L7-VL4-L8-VH4-L9-VH3-L10-CL-L11-CH1-L12-Fc; or   VH3-L7-VH4-L8-VL4-L9-VL3-L10-CL-L11-CH1-L12-F c; and   wherein:   VL1 is a first immunoglobulin light chain variable region;   VL2 is a second immunoglobulin light chain variable region;   VL3 is a third immunoglobulin light chain variable region;   VL4 is a fourth immunoglobulin light chain variable region;   VH1 is a first immunoglobulin heavy chain variable region;   VH2 is a second immunoglobulin heavy chain variable region;   VH3 is a third immunoglobulin heavy chain variable region;   VH4 is a fourth immunoglobulin heavy chain variable region;   Fc is a region comprising an immunoglobulin heavy chain constant region 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), and optionally, an immunoglobulin hinge;   CH1 is an immunoglobulin heavy chain constant region 1;   CL is an immunoglobulin light chain constant region; and   L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 and L12 are amino acid linkers.   
     
     
         131 . The antigen binding polypeptide complex of  claim 128 , wherein VH1, VL1, VH3 and VL3 bind to the same antigen. 
     
     
         132 . The antigen binding polypeptide complex of  claim 128 , wherein VH2, VL2, VH4 and VL4 bind to the same antigen. 
     
     
         133 . The antigen binding polypeptide complex of  claim 128 , wherein VH1, VH2, VH3 and VH4 each bind to different antigens, and VL1, VL2, VL3 and VL4 each bind to different antigens. 
     
     
         134 . The antigen binding polypeptide complex of  claim 128 , wherein linkers L1, L2, L3, L4, L5, L6, L7 and L8 each comprise the amino acid sequence of any one of SEQ ID NOs:1-19 and 681-688, or a sequence having at least 95% identity to any one of SEQ ID NOs:1-19 and 681-688. 
     
     
         135 . The antigen binding polypeptide complex of  claim 129 , wherein linkers L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 and L12 each comprise the amino acid sequence of any one of SEQ ID NOs:1-19 and 681-688, or a sequence having at least 95% identity to any one of SEQ ID NOs:1-19 and 681-688. 
     
     
         136 . The antigen binding polypeptide complex of  claim 130 , wherein linkers L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11 and L12 each comprise the amino acid sequence of any one of SEQ ID NOs:1-19 and 681-688, or a sequence having at least 95% identity to any one of SEQ ID NOs:1-19 and 681-688. 
     
     
         137 . The antigen binding polypeptide complex of  claim 128 , wherein the Fc region comprises at least one knob-into-hole modification. 
     
     
         138 . The antigen binding polypeptide complex  claim 129 , wherein the Fc region comprises at least one knob-into-hole modification. 
     
     
         139 . The antigen binding polypeptide complex of  claim 130 , wherein the Fc region comprises at least one knob-into-hole modification. 
     
     
         140 . An antibody or antigen binding fragment thereof comprising the antigen binding polypeptide complex of  claim 128 . 
     
     
         141 . The antibody or antigen binding fragment thereof of  claim 140 , wherein the antigen binding fragment is a Fab, scFab, Fab′, F(ab′)2, Fv, or scFv. 
     
     
         142 . The antibody or antigen binding fragment thereof of  claim 140 , wherein the antibody is human or humanized. 
     
     
         143 . A polypeptide having at least 95% identity to any one of SEQ ID NOs:32-43, 62-79, 130-138, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, and 679, or having at least 95% identity to the amino acid sequence of SEQ ID NOs:32 or 33 that does not contain the eight histidine residues at the C-terminus. 
     
     
         144 . A polynucleotide having at least 95% identity to any one of SEQ ID NOs:44-55, 80-97, 139-147, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, and 680. 
     
     
         145 . A vector comprising the polynucleotide of  claim 144 . 
     
     
         146 . A host cell comprising the polynucleotide of  claim 144 . 
     
     
         147 . A pharmaceutical composition comprising (i) the antigen binding polypeptide complex of  claim 128 , and (ii) a pharmaceutically acceptable carrier. 
     
     
         148 . A pharmaceutical composition comprising (i) a polynucleotide encoding the antigen binding polypeptide complex of  claim 128 , and (ii) a pharmaceutically acceptable carrier. 
     
     
         149 . A method of treating or preventing a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the antigen binding polypeptide complex of  claim 128 . 
     
     
         150 . A method of treating or preventing a virus infection, comprising administering to a subject in need thereof a therapeutically effective amount of the antigen binding polypeptide complex of  claim 128 .

Join the waitlist — get patent alerts

Track US2023203199A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.